MA13.07 GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC

Sugemalimab is a full-length, fully human PD-L1 targeted immunoglobin G4 (IgG4, s228p) mAb. GEMSTONE-302 randomized, double-blind, phase 3 study to evaluate the efficacy and safety of sugemalimab or placebo in combination with chemotherapy as first-line treatment metastatic squamous (sq) non-squamous (nsq) NSCLC. The PFS interim analysis data 08 June 2020 showed that plus demonstrated clinically meaningful statistically significant prolongation well-tolerated profile NSCLC patients irrespective tumor pathology expression.